Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ACE2-based decoy receptors for SARS coronavirus 2.

Proteins - 1 Sept 2021

Jing Wenyang, Procko Erik

Abstract excerpt

SARS coronavirus 2 is neutralized by proteins that block receptor-binding sites on spikes that project from the viral envelope. In particular, substantial research investment has advanced monoclonal antibody therapies to the clinic where they have shown partial efficacy in reducing viral burden and hospitalization. An alternative is to use the host entry receptor, angiotensin-converting enzyme 2 (ACE2), as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin-Converting Enzyme 2
Share to Immunoglobulin Fc Fragments
Share to Molecular Mimicry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nanoparticles

Share to Protein Binding

Share to Receptors, Virus

Share to Recombinant Fusion Proteins

Share to SARS-CoV-2

Source

Open in PubMed Open full text

Identifiers

PMID: 33973262
DOI: 10.1002/prot.26140
PMCID: PMC8242511

Genes

ACE2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ACE2-based decoy receptors for SARS coronavirus 2.PMID 33973262Read ↗

Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity Read ↗

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitorsSemantic proximity Read ↗

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.Semantic proximity Read ↗

A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.Semantic proximity Read ↗

Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variantsSemantic proximity Read ↗

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2Semantic proximity Read ↗

Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.Semantic proximity Read ↗

An ACE2 Triple Decoy that neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.Semantic proximity Read ↗

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsSemantic proximity Read ↗

An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity Read ↗

Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.Semantic proximity Read ↗

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.